DelveInsight’s Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver disease and type 2 diabetes ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

Some weight loss drugs may cause hair loss. While it’s typically a temporary side effect, it can affect your confidence.

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research materials to sidestep regulatory scrutiny.

Nearly 150 new Florida laws went into effect on July 1 after Gov. Ron DeSantis signed 11 more the day before. Here is what each law means for you.

MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...

In April 2025, Ascletis reported early weight loss results from a Phase Ib trial of ASC30. "Ascletis begins dosing in Phase IIa trial of ASC30 for obesity treatment" was originally created and ...

Research shows promising results for a weekly injectable Parkinson's treatment that maintains consistent medication levels, ...